Literature DB >> 27791171

Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.

Brian G Pierce1, Zhen-Yong Keck2, Patrick Lau2, Catherine Fauvelle3,4, Ragul Gowthaman5, Thomas F Baumert3,4,6, Thomas R Fuerst5, Roy A Mariuzza5, Steven K H Foung7.   

Abstract

The E2 envelope glycoprotein is the primary target of human neutralizing antibody response against hepatitis C virus (HCV), and is thus a major focus of vaccine and immunotherapeutics efforts. There is emerging evidence that E2 is a highly complex, dynamic protein with residues across the protein that are modulating antibody recognition, local and global E2 stability, and viral escape. To comprehensively map these determinants, we performed global E2 alanine scanning with a panel of 16 human monoclonal antibodies (hmAbs), resulting in an unprecedented dataset of the effects of individual alanine substitutions across the E2 protein (355 positions) on antibody recognition. Analysis of shared energetic effects across the antibody panel identified networks of E2 residues involved in antibody recognition and local and global E2 stability, as well as predicted contacts between residues across the entire E2 protein. Further analysis of antibody binding hotspot residues defined groups of residues essential for E2 conformation and recognition for all 14 conformationally dependent E2 antibodies and subsets thereof, as well as residues that enhance antibody recognition when mutated to alanine, providing a potential route to engineer E2 vaccine immunogens. By incorporating E2 sequence variability, we found a number of E2 polymorphic sites that are responsible for loss of neutralizing antibody binding. These data and analyses provide fundamental insights into antibody recognition of E2, highlighting the dynamic and complex nature of this viral envelope glycoprotein, and can serve as a reference for development and rational design of E2-targeting vaccines and immunotherapeutics.

Entities:  

Keywords:  HCV; alanine scanning; clustering; hotspots; immune recognition

Year:  2016        PMID: 27791171      PMCID: PMC5111724          DOI: 10.1073/pnas.1614942113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

Review 1.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

2.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.

Authors:  Michelle C Sabo; Vincent C Luca; Jannick Prentoe; Sharon E Hopcraft; Keril J Blight; Minkyung Yi; Stanley M Lemon; Jonathan K Ball; Jens Bukh; Matthew J Evans; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Authors:  Justin R Bailey; Lisa N Wasilewski; Anna E Snider; Ramy El-Diwany; William O Osburn; Zhenyong Keck; Steven K H Foung; Stuart C Ray
Journal:  J Clin Invest       Date:  2014-12-15       Impact factor: 14.808

5.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

6.  Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Authors:  Muriel Lavie; Stéphane Sarrazin; Roland Montserret; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Karin Séron; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

7.  Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.

Authors:  Zhen-yong Keck; Christine Girard-Blanc; Wenyan Wang; Patrick Lau; Adam Zuiani; Felix A Rey; Thomas Krey; Michael S Diamond; Steven K H Foung
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

Review 8.  Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?

Authors:  Christopher M Walker; Arash Grakoui
Journal:  Curr Opin Immunol       Date:  2015-08-01       Impact factor: 7.486

9.  Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.

Authors:  Florian Douam; Viet Loan Dao Thi; Guillemette Maurin; Judith Fresquet; Dimitri Mompelat; Mirjam B Zeisel; Thomas F Baumert; François-Loïc Cosset; Dimitri Lavillette
Journal:  Hepatology       Date:  2014-01-28       Impact factor: 17.425

10.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

View more
  41 in total

1.  Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.

Authors:  Huahao Fan; Luhua Qiao; Kyung-Don Kang; Junfen Fan; Wensheng Wei; Guangxiang Luo
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance.

Authors:  Valerie J Kinchen; Guido Massaccesi; Andrew I Flyak; Madeleine C Mankowski; Michelle D Colbert; William O Osburn; Stuart C Ray; Andrea L Cox; James E Crowe; Justin R Bailey
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

Review 3.  Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Authors:  Valerie J Kinchen; Andrea L Cox; Justin R Bailey
Journal:  Trends Microbiol       Date:  2018-04-24       Impact factor: 17.079

4.  Structure-Based Design of Hepatitis C Virus Vaccines That Elicit Neutralizing Antibody Responses to a Conserved Epitope.

Authors:  Brian G Pierce; Elisabeth N Boucher; Kurt H Piepenbrink; Monir Ejemel; Chelsea A Rapp; William D Thomas; Eric J Sundberg; Zhiping Weng; Yang Wang
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

5.  Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.

Authors:  Michelle D Colbert; Andrew I Flyak; Clinton O Ogega; Valerie J Kinchen; Guido Massaccesi; Mayda Hernandez; Edgar Davidson; Benjamin J Doranz; Andrea L Cox; James E Crowe; Justin R Bailey
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

Review 6.  To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.

Authors:  Felicia Schlotthauer; Joey McGregor; Heidi E Drummer
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

Review 7.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 8.  Hepatitis C Virus Glycan-Dependent Interactions and the Potential for Novel Preventative Strategies.

Authors:  Emmanuelle V LeBlanc; Youjin Kim; Chantelle J Capicciotti; Che C Colpitts
Journal:  Pathogens       Date:  2021-06-01

Review 9.  Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development.

Authors:  Eric A Toth; Andrezza Chagas; Brian G Pierce; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-29       Impact factor: 5.048

10.  Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization.

Authors:  Brian G Pierce; Zhen-Yong Keck; Ruixue Wang; Patrick Lau; Kyle Garagusi; Khadija Elkholy; Eric A Toth; Richard A Urbanowicz; Johnathan D Guest; Pragati Agnihotri; Melissa C Kerzic; Alexander Marin; Alexander K Andrianov; Jonathan K Ball; Roy A Mariuzza; Thomas R Fuerst; Steven K H Foung
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.